Clinical practice recommendations - defining an early IL-1 inhibition strategy as part of Still´s disease management plan

CLICK HERE TO REGISTER

VIRTUAL EVENT

20TH May 2021, 17.00–18.30 CET

Agenda

- **Welcome and introduction**
  Prof. F De Benedetti (Chairman)
- **Still´s disease across children and adult populations**
  Prof. B Fautrel
- **What is the role of biomarkers in diagnosis and management in Still´s disease**
  Dr. C Kessel
- **SHARE, Review current and emerging clinical practice guidelines and recommendations for management of Still´s disease in children**
  Dr. S Vastert
- **Understand treatment recommendations for biologic therapy in AOSD**
  Prof. L Dagna
- **Define where Kineret® can be an early IL-1 therapy choice to achieve and sustain patient goals in Still´s disease**
  Prof. F De Benedetti
- **Final discussion. Q&As**
  All

Sobi products will be discussed at this meeting.

This virtual promotional meeting is initiated and funded by Sobi.
This is an international webinar for invited healthcare professionals only.

Please note that prescribing information provided here may vary to the local approval in each country. Always consult your country specific SmPC for local prescribing information. You should review your local Summary of Product Characteristics and consult directly your local Sobi affiliate to address any questions.

Sobi products, as well as other IL-1 blockers, will be discussed in this meeting. All information on Kineret® use in Still's disease is based on the approved EU label.

PP-11436/05-2021 Date of preparation: April 2021

sobi
rare strength

Prof. Fabrizio De Benedetti

Gesù Children's Hospital, Rome, Italy

Professor Fabrizio De Benedetti received his MD and PhD from the University of Pavia where he trained as a Paediatric Rheumatologist. Since the end of 2003, he has been working at the Bambino Gesù Children Hospital in Rome where he serves as Head of the Division of Pediatric Rheumatology and the Head of the Laboratory of ImmunoRheumatology.

His main clinical and research interests lie in the pathogenesis of, and particularly on the role of inflammatory cytokines in, paediatric inflammatory diseases. His research has led to the identification of novel biomarkers of disease activity and prognosis in several rheumatic diseases of children and, more importantly, to the identification of novel therapeutic targets and the design and implementation of pivotal registration clinical trials. While leading the clinical division at his current affiliation, he has, as Lead Principal Investigator, designed, coordinated, or is coordinating, over 10 phase 2/3 clinical trials with novel targeted therapies in paediatric rheumatic diseases. He has authored approximately 180 peer-reviewed publications.

CLICK HERE TO REGISTER

VIRTUAL EVENT

Prof. Bruno Fautrel

Hopital de la Pitié Salpétrière, Paris, France

Bruno Fautrel is Professor of Rheumatology at the Pitié Salpêtrière University Hospital at Sorbonne University / Assistance Publique-Hôpitaux de Paris Health Care Center in Paris, France.

After completing his residency in rheumatology at the Paris Medical School and an immunology Masters Degree at the Pasteur Institute, he spent a year out in Canada as a post-doctoral fellow at the Division of Clinical Epidemiology at the McGill University Health Center in Montreal. Back to France, he continued and developed his commitment in clinical epidemiology, health service research and health economics through a PhD thesis at the Nancy University.

He has participated in constructing and conducting several French national cohort studies, including ESPOIR (early arthritis), DESIR (early spondyloarthritis), KHOALA (osteoarthritis of the lower limbs), MAJIK (inflammatory rheumatism treated with jak inhibitors) and ACOSTILL (adult onset Still's disease and systemic onset juvenile idiopathic arthritis). He has been head of the ESPOIR Cohort Scientific Committee (2008 to 2010) and of the Scientific Committee of the French Society of Rheumatology (2010 to 2011).

Bruno Fautrel has also been the principal investigator of 2 multicenter trials on the decline of targeted therapies in rheumatoid arthritis, and co-piloted as coordinating investigator a European project on a multiomic approach to the diagnosis of autoinflammatory diseases.

Bruno is currently head of the Department of Rheumatology of the Pitié Salpêtrière University Hospital, and active member of the PEPITES team (PharmacoEPIdemiologie eT Evaluation des Soins, Pharmacoepidemiology and Care assessment) in the Pierre Louis Institute of Epidemiology and Public Health (INSERM Sorbonne University UMR S1136). He is also the co-director of the IMIDIATE clinical research network, a nationwide network dedicated to clinical investigations in immune-mediated inflammatory diseases.

Dr. Christoph Kessel

Münster University, Germany

Dr Christoph Kessel is an immunologist and leader of the group for Translational Inflammation Research within the Department of Pediatric Rheumatology and Immunology at Münster University Children's Hospital, Germany. His primary research interest is on understanding of disease mechanisms and biomarkers in the context of systemic rheumatic diseases, with a particular focus on systemic JIA and Macrophage Activation Syndrome.

Dr Kessel graduated in Biosciences and obtained a PhD from Goethe-University Frankfurt, Germany. In 2009 he joined Rikard Holmdahl and Medical Inflammation Research at Karolinska Institute (Stockholm, Sweden) for postdoctoral training. Following his interest in studying particularly innate immune functions in inflammation in a translational research setting he joined Dirk Foells team at Muenster University Medical Center in 2012. Together with Drs. Claudia Bracaglia, Francesca Minoia and Sebastiaan Vastert, Dr Kessel is steering the systemic JIA and Macrophage Activation Syndrome working party of the Pediatric Rheumatology European Society (PReS), where he is responsible for coordinating science and research.

CLICK HERE TO REGISTER

VIRTUAL EVENT

Dr. Sebastiaan J. Vastert

University Medical Center Utrecht, Netherlands

Bas Vastert (1975) is a pediatric rheumatologist in the Wilhelmina Children's Hospital Utrecht. He obtained his PhD in mechanisms of disease and therapy in severe Juvenile Idiopathic Arthritis in 2013. From 2013, he started a translational research line in the laboratory of translational immunology and from March 2017 he is co-heading the v Loosdregt-Vastert group within the Laboratory of Translational Immunology in UMC Utrecht, focusing on novel therapeutic strategies in JIA through translation of cutting edge basic science into clinical benefit. He is currently leading a multicenter prospective trial implementing a biomarker driven stopstrategy for rIL-1RA therapy in systemic JIA in the Netherlands. His lab is also one of the lead laboratory groups in UCAN CAN DU, the Dutch Canadian collaborative consortium aiming for personalized medicine for JIA.

Prof. Lorenzo Dagna

San Raffaele Hospital Milano, Italy

Lorenzo Dagna graduated in Medicine and is Board Certified in Internal Medicine. He is currently Associate Professor of Medicine at Vita-Salute San Raffaele University, in Milano, Italy. Prof. Dagna is Head of the Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR) at IRCCS San Raffaele Scientific Institute, Milano.

The clinical activity of Prof. Dagna is primarily focused on the care of patients with immunological and rheumatic diseases, in particular those with rare immune-mediated disorders. He is also involved in both basic and clinical research on the immunopathogenesis and immunotherapy of those diseases. Lorenzo Dagna is a Fellow of the American College of Physician (ACP), Honorary Fellow of the European Federation of Internal Medicine (EFIM), and member of the Italian Society for Internal Medicine (SIMI) and Italian Society of Rheumatology (SIR). He serves as the Section Editor for Immunology and Rheumatology for the European Journal of Internal Medicine.

Prof. Dagna is Chair of the Rare Disease Working Group of the European Federation of Internal Medicine (EFIM), Member of the Commission Expert Group on Rare Diseases of the European Commission (Luxembourg, L), Alternate Member of the Healthcare Professionals Working Party of the European Medicine Agency (EMA, London, UK), Board Member of the Foundation for the Development of Internal Medicine in Europe (FDIME, Geneva), Member of the Medical Advisory Board of the Erdheim-Chester Global Alliance (DeRidder, LA), member of the Rare and Underdiagnosed Multidisciplinary Joint Committee of the European Union of Medical Specialists (UEMS).